Evaluating the Therapeutic Impact of Immune Checkpoint Inhibitors in the Management of Brain Metastases from Non-Small Cell Lung Cancer
More research is needed to fully understand the efficacy of ICIs in treating BMs. Future prospective studies must include patients with active and symptomatic BMs to validate these findings and provide a clearer picture of ICI efficacy in this patient population.
Authors
- Mohnnad Asla
- Ashraf Abu Jama
- Mahmoud Abu Amna (ORCID: https://orcid.org/0000-0003-0571-9287)
- Marek Juda (ORCID: https://orcid.org/0000-0002-0340-5463)
- Walid Shalata (ORCID: https://orcid.org/0000-0002-7570-4550)
- K. Rouvinov
- Raneen Naamneh
- Sofyan Abu Freih (ORCID: https://orcid.org/0000-0001-8613-4752)
- Arina Soklakova
- Nashat Abu Yasin
- Alexander Yakobson
- Wenad Najjar
- Yotam Malek
Institutions
- Ben-Gurion University of the Negev (IL)
- Hadassah Medical Center (IL)
- Soroka Medical Center (IL)
Publication Details
- Journal
- Biomedicines
- Published
- 2026-03-02
- DOI
- https://doi.org/10.3390/biomedicines14030566
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00